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ABSTRACT
Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute
myeloid leukemia (AML) in children is presented and critically evaluated in this systematic evidence-based review.
Specific criteria were used for searching the published literature and for grading the quality and strength of the
evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence
are presented in the table entitled “Summary of Treatment Recommendations Made by the Expert Panel for
Pediatric Acute Myeloid Leukemia” and were reached unanimously by a panel of experts in AML. The identified
priority areas of needed future research in pediatric AML include: What is the role of risk group stratification,
including the role of cytogenetics, in selection of patients for allogeneic SCT, especially those in first CR? What is
the appropriate timing and use of alternative donor SCT, given that matched unrelated donor SCT appears to yield
outcomes equivalent to matched related donor SCT?What is the role of reduced intensity SCT (including the use
of fludarabine-based preparative regimens) and/or other immunomodulatory approaches to maximize the graft-
versus-leukemic effect? and What is the role of biologically targeted agents (ie, tyrosine kinase inhibitors, farnesyl
transferase inhibitors, Flt-3 inhibitors, etc) in the treatment of AML, including induction, consolidation, condi-
tioning regimens, and after SCT?
© 2007 American Society for Blood and Marrow Transplantation
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[NTRODUCTION
The American Society for Blood and Marrow
ransplantation in 1999 began an initiative to sponsor
vidence-based reviews of the scientiﬁc and medical
iterature for the use of blood and marrow stem cell
ransplantation (SCT) in the therapy of selected dis-
ases. The steering committee that was convened to tversee the projects invited an independent panel of
isease-speciﬁc experts to conduct each review. Four
revious reviews have been published in Biology of
lood and Marrow Transplantation on diffuse large cell
cell non-Hodgkin lymphoma [1], multiple myeloma
2], pediatric ALL [3], and adult ALL [4].
This is the ﬁfth review to result from this initia-ive. Its goals are to assemble and critically evaluate all
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D. M. Oliansky et al.2f the evidence regarding the role of SCT in the
herapy of pediatric (21 yr) patients with acute my-
loid leukemia (AML) make treatment recommenda-
ions based on the available evidence, and identify
eeded areas of research.
ITERATURE SEARCH METHODOLOGY
PubMed and Medline, the Web sites developed by
he National Center of Biotechnology Information at
he National Library of Medicine of the National
nstitutes of Health, were searched August 9, 2005
sing the search terms “acute myeloid leukemia” or
acute myelogenous leukemia” and “transplant” lim-
ted to human trials, English language, and publica-
ion date of 1990 or later. An updated search was
onducted on February 9, 2006, limited to the period
rom July 1, 2005 to March 1, 2006. Articles were
xcluded if published before 1990, included 25 pa-
ients, were not peer reviewed, were editorials, letters
o the editor, phase I (dose escalation or dose ﬁnding)
tudies, reviews, consensus conference papers, practice
uidelines, laboratory studies with no clinical corre-
ates, did not focus on an aspect of therapy with SCT
or the treatment of pediatric AML, or if50% of the
tudy population was 21 years of age. In addition,
or an article to be included, 70% of study subjects
ad to have AML or study results had to be stratiﬁed
able 1. Grading the Quality of Design and Strength of Evidence
Levels
 High-quality meta analyses, systematic reviews of randomiz
 Well-conducted meta analyses, systematic reviews of RCTs
 Meta-analyses, systematic reviews of RCTs, or RCTs with a
 High-quality systematic reviews of case-control or cohort s
High-quality case-control or cohort studies with a very low
relation is causal
 Well-conducted case control or cohort studies with a low r
the relation is causal
 Case control or cohort studies with a high risk of confound
Nonanalytic studies, eg, case reports, case series
Expert opinion
eprinted with permission from Harbour R, Miller J. A new syste
2001;323:334–336.
able 2. Grading the Strength of the Treatment Recommendation
Grades of R
At least one meta-analysis, systematic review, or randomi
target population; or A systematic review of RCTs or a b
applicable to the target population, and demonstrating o
A body of evidence including studies rated as 2, directl
consistency of results; or Extrapolated evidence from stu
A body of evidence including studies rated as 2, directly
consistency of results; or Extrapolated evidence from stu
Evidence level 3 or 4; or Extrapolated evidence from studi
eprinted with permission from Harbour R, Miller J. A new syste
2001;323:334–336.y disease. Abstracts and presentations at national or
nternational meetings were not included as evidence
n this review for reasons previously described [3].
This search strategy did not yield any articles speciﬁc
o acute promyelocytic leukemia (APL) in children. A
earch on the speciﬁc terms “APL” and “transplant”
ielded 99 articles limited to English-language and hu-
an trials [5-8], but none of these met the inclusion
riteria described above. Because transplantation is not
he standard for the initial treatment for APL, most
tudies included in this review excluded patients with
PL or retained only a minority proportion (usually
5%) of patients with APL in their study population.
UALITATIVE AND QUANTITATIVE GRADING OF THE
VIDENCE
The hierarchy of evidence, including a grading
cheme for the quality and strength of the evidence
nd strength of each treatment recommendation, has
een established and published as an editorial policy
tatement in Biology of Blood and Marrow Transplanta-
ion (2005). Tables 1 and 2 are reprinted from the
olicy statement and deﬁne criteria used to grade the
tudies included in this review and grade the treatment
ecommendations. Study design, including sample
ize, patient selection criteria, duration of follow-up,
nd treatment plan also were considered in evaluating
ence
trolled trials (RCTs), or RCTs with a very low risk of bias
Ts with a low risk of bias
isk of bias
confounding, bias, or chance and a high probability that the
onfounding, bias, or chance and a moderate probability that
s, or chance and a significant risk that the relation is not causal
rading recommendations in evidence-based guidelines. Br Med J.
endation
trolled trial (RCT) rated as 1, and directly applicable to the
evidence consisting principally of studies rated as 1, directly
consistency of results
able to the target population, and demonstrating overall
ted as 1 or 1
ble to the target population and demonstrating overall
ted as 2
d as 2
rading recommendations in evidence-based guidelines. Br Med J.of Evid
ed con
, or RC
high r
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risk of
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Cytotoxic Therapy with HSCT in Pediatric AML 3he studies. Several multicenter clinical trials were
esigned to biologically assign patients to a treatment
rm based on the availability of a donor (“biologic
llocation”). Analysis of related allogeneic (allo) SCT
ersus chemotherapy is therefore graded as level “2”
vidence, not level “1”, because it is not based on a
tatistically randomized, controlled trial design. Au-
ologous (auto) SCT versus chemotherapy was graded
s level “1” evidence if the study design included a
tatistically randomized, controlled trial. Clinical
tudies are summarized with enough detail to provide
concise summary of study design, sample size, eligi-
ility criteria, and treatment schedule.
All data in the text and tables were abstracted from
he original articles ﬁrst by the ﬁrst author (DO) and
hen double checked for accuracy and clarity by 2
ther authors (TH and PLM) and 1 additional re-
iewer (see Acknowledgments). In some articles there
ere discrepancies within the data reported and, in these
ases the data most consistent with the text of the article
ere presented in this review. The last author (TH)
akes responsibility if errors remain. Appendix A lists the
ommon abbreviations used in this review.
REATMENT RECOMMENDATIONS
The strength of this review is the detail conveyed
n the text about the study designs and the presenta-
ion of the outcomes in the summary tables at the end
f each major section. Table 3 contains the summary
f treatment recommendations made by the pediatric
ML expert panel. The expert panel deliberated on
everal treatment recommendations, particularly the
se of bone marrow (BM) versus peripheral blood
PB) as the stem cell source. Most pediatric patients
ith AML have pediatric (minor) donors, which can
reate an ethical and regulatory dilemma regarding
he risks and beneﬁts of subjecting healthy minors
o stem cell donation [9,10]. Although the short-
erm risk of death or life-threatening complications
ith pediatric BM donation is established and rare
0.4%), there is little to no evidence of the long-
erm effects of growth factor administration, central
ine placement, or use of blood transfusions associated
ith pediatric PB stem cell donation. Use of BM from
healthy sibling donor, when available, is considered
tandard of care and the ethics of minor sibling dona-
ion of unstimulated BM are generally accepted. The
uestion of whether PB stem cell donation poses an
ncreased unacceptable risk compared with BM dona-
ion remains unanswered. Thus, the expert panel con-
ensus was to recommend BM as the preferred stem
ell source in the matched related donor allo-SCT
etting. This issue is not applicable in the auto-SCT
etting, because the donor is the patient and obviates
he ethical issues. It is also not applicable with unre- aated donor allo-SCT, because all unrelated BM and
B donors are 18 years of age.
MT VERSUS CHEMOTHERAPY IN PEDIATRIC AML
Evidence is taken from self-described studies of
ediatric populations, all of which included patients
21 years of age. The highest quality studies are
resented ﬁrst; studies of equal quality are presented
n descending order by sample size. The following text
escribes the study design of each of the 16 articles
ncluded in this section. Table 4 presents a summary
f the outcomes for each study. Of the 6 studies
nvestigating auto-BMT versus chemotherapy only, 1
tudy found a signiﬁcant difference in DFS between
he 2 treatment groups. Of the 16 studies that exam-
ned allo-BMT versus chemotherapy only with/with-
ut auto-BMT, 6 stated a statistically signiﬁcant dif-
erence in DFS between treatment groups and 3 found
signiﬁcant difference in overall survival (OS).
utologous BMT versus Chemotherapy in First
R
Alonzo et al. [11] reported the cumulative out-
omes of 1464 pediatric (21 yr) patients with AML
ho achieved ﬁrst CR (CR1) in the 5 Children’s
ancer Group (CCG) trials (CCG 251, 213, 2861,
891, 2941) presented in detail below or in other
ections of this review. Children diagnosed with APL,
yelodysplastic syndrome (MDS), or Down syn-
rome (DS) were excluded from these trials. Of the
464 patients, 186 had unknown data or withdrew
rom study before assignment. The remaining patients
ere assigned to allo-BMT (n  373) if a human
eukocyte antigen (HLA)-matched related donor was
vailable, auto-BMT (n 217), or chemotherapy (n
88). Approximately 15% of children did not receive
he treatment to which they were assigned. Figure 1
ompares the disease-free survival (DFS) between the
onor and no-donor groups.
Woods et al. [12] presented the results of the
CG 2891 multicenter, randomized, prospective trial,
hich enrolled 1114 pediatric (21 yr) patients with
ML, that compared chemotherapy, auto-BMT, and
llo-BMT. Patients diagnosed with Fanconi anemia
nd philadelphia chromosome-positive (Ph) chronic
yelogenous leukemia (CML) were excluded from
he trial, and those with DS, secondary AML, granu-
ocytic sarcoma, or MDS were excluded from the
nalysis, leaving 887 analyzable patients. A total of 652
74%) patients achieved CR1. Patients with 5- or
-antigen HLA-matched family donors (n  181)
ere biologically assigned to receive allo-BMT. Of
he remaining 471 patients, 115 refused randomiza-
ion, leaving 356 patients to be randomized between
uto-BMT (n  177) or 4 cycles of 3 different con-
TT
T
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†
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D. M. Oliansky et al.4able 3. Summary of Treatment Recommendations Made by the Expert Panel for Pediatric Acute Myeloid Leukemia
Indication for HSCT
Treatment
Recommendation
Grade
Highest Level
of Evidence†
Reference
No.‡ Treatment Recommendation Comments
RANSPLANTATION VERSUS CHEMOTHERAPY
Auto-SCT vs
chemotherapy in CR1
A 1 9 Auto-SCT and chemotherapy have equivalent survival
outcomes.
Lacking data on QOL, secondary malignancies and other
late effects of treatment prevents a recommendation
of one therapy over the other.
Allo-SCT vs
chemotherapy in CR1
B 2 9 Allo-SCT has superior OS and LFS compared with
chemotherapy and is recommended. Additional
prospective data regarding risk subgroups may alter
this recommendation.
Allo-SCT vs
chemotherapy in CR2
D 2 24 There is a lack of evidence comparing MRD allo-SCT
compared to chemotherapy in CR2; however, the
consensus recommendation of the expert panel is
MRD allo-SCT if available.
A MUD or other alternative donor SCT is
recommended in the context of a clinical trial.
RANSPLANTATION TECHNIQUES
Auto-SCT vs allo-SCT in
CR1
A 1 9 MRD allo-SCT has superior survival outcomes compared
to auto-SCT in CR1. Additional prospective data
regarding risk subgroups may alter this
recommendation.
The consensus recommendation of the expert panel is
to use bone marrow as the stem cell source in the
MRD allo-SCT setting based on scientific, ethical,
regulatory, and practical issues.
Auto-SCT vs allo-SCT in
CR2
C 2 25,34 The consensus recommendation of the expert panel is
to use any suitably matched related or unrelated allo-
over auto-SCT; however, there is a lack of evidence
that one has better outcomes than the other.
Auto-SCT No recommendation 2 28,35–40 Current practice is to use PBSCT; however, there are
very few patients in the 2 studies that fulfill review
criteria.
A randomized trial of Auto-BMT vs PBSCT is not
feasible due to the infrequent use of auto-SCT for
pediatric patients with AML. With current technology,
there is a preference for using MUD or alternative
donors over auto-SCT if a MRD is not available.
There are no effective purging agents currently
available, but if one were developed, it would increase
interest for a trial of purged vs unpurged auto-SCT.
Related vs unrelated
allo-SCT
D 2 41 There are no data indicating that using one type of
suitably matched allo-SCT is better than another.
There are differences between institutions with
regard to transplantation technique; however, there
are no apparent differences in outcomes across
institutions.
Related allo-SCT B 2 42–46 MRD allo-SCT is preferred in CR1 or CR2; in CR2,
alternative donors could be considered if MRD is not
available.
Unrelated allo-SCT No recommendation 2 47–49 No evidence for one preferred technique for unrelated
allo-SCT (ie, T cell depletion, cord blood vs PBSCT vs
BMT, etc).
Comparison of allo-SCT
myeloablative
conditioning regimens
C 2 50,51 There is no difference or preference of one conditioning
regimen over another with respect to survival, LFS, or
late effects.
Comparison of auto-SCT
myeloablative
conditioning regimens
No recommendation NA None No evidence comparing conditioning regimens in the
auto-SCT setting.
APL in CR1 Not recommended 4 None No evidence of a need for SCT.
APL in CR2 D 3 5–8 Standard practice is to use allo-SCT (preferred) or auto-
SCT if there is no suitable MRD, MUD, or alternative
donor, or a trial comparing haploidentical allo-vs
auto-SCT.
OL indicates quality of life; MRD, matched related donor; MUD, matched unrelated donor; LFS, leukemia-free survival; NA, not available; RCT, randomized controlled trial.
Deﬁnitions: Grade of Recommendation (Table 2): (A) At least one meta-analysis, systematic review, or RCT rated as 1 and directly applicable to the target population, or a systematic
review of RCTs or a body of evidence consisting principally of studies rated as 1, directly applicable to the target population, and demonstrating overall consistency of results; (B) a
body of evidence including studies rated as 2, directly applicable to the target population, and demonstrating overall consistency of results, or extrapolated evidence from studies rated
as 1 or 1; (C) a body of evidence including studies rated as 2, directly applicable to the target population, and demonstrating overall consistency of results, or extrapolated evidence
from studies rated as 2; (D) evidence level 3 or 4, or extrapolated evidence from studies rated as 2.
Deﬁnitions: Levels of Evidence (Table 1): 1, high-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias; 1, well-conducted meta analyses, systematic
reviews of RCTs, or RCTs with a low risk of bias; 1, meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias; 2, high-quality systematic reviews of case-control
or cohort studies, or high-quality case-control or cohort studies with a very low risk of confounding, bias, or chance and high probability that the relation is causal; 2, well-conducted
case-control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relation is causal; 2, case-control or cohort studies with a high risk
of confounding, bias, or chance and a signiﬁcant risk that the relation is not causal; 3, nonanalytic studies, eg, case reports, case series; 4, expert opinion.The references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence described in the review.
Table 4. Comparison of Patient Characteristics and Outcomes from Studies Included in the Transplantation versus Chemotherapy Section
Reference
#
Quality
&
Strength
of
Evidence* Patient Population
Patient
Characteristic† Risk Groups
Number of Patients by
Study Group
Upper
Limit
(median)
Age at
Diagnosis
%
Treatment
Related
Mortality
Median
Follow-
Up
(Months)
% DFS/
% EFS/
% RFS
(Signif)
Outcome
Defined
% OS
(Signif)
OS
Defined
Autologous BMT versus Chemotherapy in First Complete Remission (CR1)†
[11] 1 Combined 5 CCG
Trials (251, 213,
2861, 2891, 2941)
1979–1996
Meta-analysis
Age, WBC, Blast %,
Gender, FAB, Cytogen.
Not Stated Total 905 (ITT)
Auto 217
Chemo 688
<21 yrs
(6.2)
(7.0)
8-yr
7
6
Not
Stated
8-yr DFS
42  7
34  4
(P.83)
Time from CR1
to relapse or
death from any
cause
8-yr
49  7
42  4
(P.37)
Time from CR1
to death from
any cause
[12] 1 CCG Trial 2891
Oct 1989 to Apr 1995
Multi-center (236)
Randomized trial
US, Canada,
Australia
Age, WBC, FAB,
Cytogen.
Not Stated Total 356 (ITT)
Randomized Auto 177
Randomized Chemo
179
<21 yrs
(Not
Stated)
Not stated
5
4
Not
Stated
(min 4
yrs)
8-yr DFS
42  8
47  8
(P.31)
Time from CR1
(event not
defined)
8-yr
48  8
53  8
(P.21)
Time from CR1
(event not
defined)
[13] 1 POG Trial 8821
Jun 1988 to Mar 1993
Multi-center (16)
Randomized trial
US
Race, Age, WBC, FAB,
EMD, Induction response,
DS, Cytogen.
Not Stated Total 232 (ITT)
Randomized Auto 115
Randomized Chemo
117
<21 yrs
(Not
Stated)
Not stated
15
2.7
Not
Stated
3-yr EFS
38  6.4
36  5.8
(P.20)
Time from
randomization
until 1st event
3-yr
40  6.1
44  6.0
(P.10)
Time from
randomization
until death
[14] 1 UK-MRC 10th AML
May 1988 to Mar
1995
Multi-center (41)
Randomized trial
UK, Rep. of Ireland,
New Zealand
Sex, Age, FAB, AML type,
CNS, WBC Cytogen.
Good‡
(28%)
Standard
(52%)
Poor (20%)
Total 100 (ITT)
Randomized Auto 50
Random. no Therapy
50
<15 yrs
(Not
Stated)
Not Stated Not
Stated
7-yr DFS
68
46
(P.02)
Time from CR1
to any event
7-yr
70
59
(P.20)
Time from
entry
to death
[15] 1 AIEOP LAM 87
Mar 1987 to Mar
1990
Randomized trial
Multi-center (29)
Italy
Age, Sex, WBC, FAB, EMD,
Platelets, Time to CR1,
Hepato., Splenom.
Not Stated Total 72 (ITT)
Randomized Auto 35
Randomized Chemo 37
<15 yrs
(7 yrs)
Not Stated
3
8
28 mos 5-yr DFS
21  8
27  8
(Not Signif.)
Time from CR1
to 1st event
Not
Stated
[16] 2 Combined AIEOP
LAM 87–92 Trials
Mar 1982 to Sep 2001
Retrospective
Age, Sex, WBC, CNS,
FAB, Cytogen.
SR, HR
(LAM 92
only)
Total 199
Auto 110
Chemo 89
<15 yrs
(Not
Stated)
Not Stated Not
Stated
5-yr DFS
55  5
28  5
(Not
Stated)
Time from CR1
to last follow-up
or first event
Not
Stated
Allogenic BMT vs Chemotherapy  Autologous BMT in CR1
[11] 2 Combined 5 CCG
Trials
(251, 213, 2861, 2891,
2941)
1979-1996
Meta-analysis
Age, WBC, Blast %,
Gender, FAB, Cytogen.
Not Stated Total 1278 (ITT)
Allo 373
Auto 217
Chemo 688
<21 yrs
(8.9)
(6.2)
(7.0)
8-yr
17
7
6
Not
Stated
8-yr DFS
47  5
42  7
34  4
(Allo vs
Chemo
P.004)
Time from CR1
to relapse or
death from any
cause
8-yr
54  5
49  7
42  4
(Allo vs
Chemo
P.06)
Time from CR1
to death from
any cause
Cytotoxic
Therapy
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Table 4. Continued
Reference
#
Quality
&
Strength
of
Evidence* Patient Population
Patient
Characteristic† Risk Groups
Number of Patients by
Study Group
Upper
Limit
(median)
Age at
Diagnosis
%
Treatment
Related
Mortality
Median
Follow-
Up
(Months)
% DFS/
% EFS/
% RFS
(Signif)
Outcome
Defined
% OS
(Signif)
OS
Defined
[12] 2 CCG Trial 2891
Phase III
Oct 1989 to Apr 1995
Multi-center (236)
US, Canada,
Australia
Age, WBC, FAB,
Cytogen.
Not Stated Total 537 (ITT)
Allo 181
Randomized Auto 177
Randomized Chemo
179
<21 yrs
(Not
Stated)
Not stated
14
5
4
Not
Stated
(min 4
yr)
8-yr DFS
55  9
42  8
47  8
(Allo vs
Chemo
P.01)
Time from CR1
(event not
defined)
8-yr
60  9
48  8
53  8
(Allo vs
Chemo
P.05)
Time
from CR1
(event not
defined)
[13] 2 POG Trial 8821
Jun 1988 to Mar 1993
Multi-center (16)
US
Race, Age, WBC, FAB,
EMD, Induction response,
DS, Cytogen.
Not Stated Total 321 (ITT)
Allo 89
Randomized Auto 115
Randomized Chemo
117
<21 yrs
(Not
Stated)
Not stated
Not stated
15
2.7
Not
Stated
3-yr EFS
52  8
38  6.4
36  5.8
(Allo vs
Chemo
P.06)
Time from
randomization
until 1st event
3-yr
Not Stated
40  6.1
44  6.0
(Allo vs
Chemo
P.15)
Time from
date of
randomization
until death
[14] 2 UK-MRC 10th AML May
1988 to Mar
1995
Multi-center (41)
UK, Rep. of Ireland,
New Zealand
Sex, Age, FAB,
AML type, CNS,
WBC, Cytogen.
Good*
(28%)
Standard
(52%)
Poor (20%)
Total 315 (ITT)
Donor 85
No Donor 230
<15 yrs
(Not
Stated)
Not Stated
9
1
Not
Stated
Not Stated Time from CR1
to any event
7 yr
70
60
(P.10)
Time from
entry
to death
[15] 2 AIEOP LAM 87
Mar 1987 to Mar
1990
Multi-center (29)
Italy
Age, Sex, WBC, FAB, EMD,
Platelets, Time to CR1,
Hepato, Splenom.
Not Stated Total 96 (ITT)
Allo 24
Randomized Auto 35
Randomized Chemo 37
<15 yrs
(7 yrs)
Not Stated
0
3
8
28 mos 5-yr DFS
34  10
21  8
27  8
(Allo vs
Other
P.03)
Time from CR1
to 1st event
Not
Stated
[16] 2 Combined AIEOP
LAM 87–92 Trials
Mar 1982 to Sep 2001
Retrospective
Age, Sex, WBC, CNS,
FAB, Cytogen.
SR, HR
(LAM 92
only);
Favorable
cytogen.§ vs
Other
Total 277
Allo 78
Auto 110
Chemo 89
<15 yrs Not Stated Not
Stated
5-yr DFS
64  6
55  5
28  5
(Allo vs
Other
P-value
Not Stated)
Time from CR1
to last follow-up
or first event
Not
Stated
[17] 2 CCG 213 Trial
Jan 1986 to Feb 1989
Multi-center (35)
US and Canada
Age, Sex, Race,
WBC, FAB
Not Stated Total 411 (ITT)
Donor 113
No Donor 298
<22 yrs
(Not
Stated)
Not Stated 5.3 yrs
(63.6
mos)
5-yr DFS
46 (CI 36–
56)
38 (CI 32–
44)
(P.06)
Time from end of
induction to
relapse or
death
5-yr
52
(CI 42–62)
46
(CI 36–56)
(P.13)
Time from end
of induction
to death
[18] 2 CCG 251 Trial
Sept 1979 to Oct
1983
Multi-center (34)
US and Canada
Age, Sex, WBC, FAB Not Stated Total 381 (ITT)
Donor 89
No Donor 252
<21 yrs
48% <8 y
60% <8 y
Not Stated 5 yrs
(60
mos)
5-yr DFS
45
33
(P<.05)
Time from SCT
to relapse or
death from any
cause
5-yr
50
36
(P<.05)
Time from SCT
to death from
any cause D.
M
.
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Table 4. Continued
Reference
#
Quality
&
Strength
of
Evidence* Patient Population
Patient
Characteristic† Risk Groups
Number of Patients by
Study Group
Upper
Limit
(median)
Age at
Diagnosis
%
Treatment
Related
Mortality
Median
Follow-
Up
(Months)
% DFS/
% EFS/
% RFS
(Signif)
Outcome
Defined
% OS
(Signif)
OS
Defined
[19] 2 LAME 89, LAME 91
and LAME SP Trials
1989-1998
Multi-center (18)
Age, Sex, WBC,
FAB, Cytogen.
Favorable vs
Others
(LAME
89/91 only)
Total 277
Allo 74
Chemo 203
< 20 yrs
(6.9
yrs)
Not Stated Not
Stated
5-yr DFS
57  7
52  4
(P.18)
Time from CR1
to 1st event
5-yr
70.5  7
55.4  4
(P.006)
Time from DX
1st event or
last follow-up
[21] 2 NOPHO-AML93
Jan 1993 to Dec 2000
Multi-center (21)
Denmark, Finland,
Iceland, Norway,
Sweden
Age, Sex, WBC, CNS,
FAB, Induction response,
Cytogen.
Not Stated Total 200 (ITT)
Allo 53
Chemo 147
<18 yr
(6 yrs)
Not Stated Not
Stated
7-yr DFS
64
51
(P.04)
Time from CR1
to relapse
or death
7-yr
69
71
(Not
Signif.)
Time from CR1
to death
[22] 2 EORTC 58921
Oct 1992 to Dec
2000
Multi-center (21)
Europe
Sex, Age, WBC, CNS,
FAB, Cytogen.
Favorable
(15%)
Intermed.
(25%)
Unfavorable
(60%)
Total 145 (ITT)
Donor 39
No Donor 106
<18 yrs
(6 yrs)
5 yr
8
3
5.5 yr
(66
mos)
5-yr DFS
63  13
57  5
(Not
Stated)
Time from CR1
to date of
first event or
last follow-up
5-yr
78  7
65  5
(Not
Stated)
Time from CR1
to death or
last follow-up
[23] 2 TPOG-AML-97A
Jan 1997 to Dec 2002
Multicenter
Taiwan
Age, Sex, WBC, FAB,
Cycles to CR1,
CNS, Cytogen.
Not Stated Total 105 (ITT)
SCT 29¶
Chemo 76
<18 yrs
(Not
Stated)
Not Stated Not
Stated
5-yr DFS
60  9.5
68  5.4
(P.63)
Time from SCT
to failure
Not
Stated
[24] 2 AML-80 Trial
Apr 1980 to Oct
1983
Multi-center (7)
US
Age, Sex, Race, WBC,
FAB, CNS, Platelets,
Auer rods, Coag.
Abnorm.
Not Stated Total 61 (ITT)
Allo 19
Chemo 42
<20 yrs
(11.3)
Not Stated
26
5
6 yrs
(72
mos)
6-yr DFS
43  13
31  7
(P.30)
Time from CR1
to relapse
or death due
to any cause
Not
Stated
[25] 2 CCG 2941
Jan 1995 to Feb 1996
Multi-center (10)
US
Age, Sex, Race,
WBC, EMD, FAB
Not Stated Total 57 (ITT)
Allo 14
Chemo 43
<20
(Not
Stated)
Not Stated
22
(Overall)
Not
Stated
3-yr DFS
46  14
53  8
(P.70)
Time from CR1
to relapse
or death from
disease
progress.
3-yr
63  13
69  7
(P.14)
Not Stated
[26] 2 CCG Trial 2951
Aug 1997 to Jan 2000
Multi-center (11)
US
Age, Sex, Race, WBC,
FAB, Splen., Hepato.,
Platelets, CR1
Duration, Cytogen.
Not Stated Total 48
Allo 35
Chemo 13
<22 yrs
(10.2
yrs)
Not Stated
37
15
17.6 mos
15.5 mos
2-yr DFS
43
51
(Not Signif.)
Time from CR
to relapse
or death
2-yr
40
50
(Not Signif.)
Time from start
of therapy
to death
ITT indicates intent to treat; DX, diagnosis; Chemo, chemotherapy; CCG, Children’s Cancer Group; POG, Pediatric Oncology Group; MRC, Medical Research Council; AIEOP, Associazione Italiana Ematologia ed Oncologia Pediatrica; LAM, Leucemia Acuta
Mieloide; NOPHO, Nordic Society for Paediatric Haematology and Oncology; LAME, Leucémie Aiguë Myéloblastique Enfant; EORTC, European Organization of Research and Treatment of Cancer; TPOG, Taiwan Pediatric Oncology Group; RFS, relapse-free
survival; WBC count, WBC count at diagnosis; EMD, extramedullary disease; SR, standard risk; HR, high risk.
*Quality and strength of evidence deﬁnitions are listed in Table 1.
†Auto versus allo outcomes are presented in Table 5.
‡Stevens et al. [14]: good indicates (8;21), t(15;17), M3, inv(16); poor, 1 induction, monosomy 5 or 7, del(5q), abnormal 3q, 4 abnormalities; standard indicates all other patients.
§Pession et al. [16]: favorable cytogenetics indicates t(8;21), inv(16), t(15;17).
Entz-Werle et al. [22] according to Keating risk classiﬁcation (Keating et al., Leukemia. 1988;2:403–412): favorable indicates t(8;21), inv(16), t(15;17); intermediate, all others; unfavorable, t(9;11), 5, 5q, 7, 7q, complex abnormalities.
¶79%  allo-SCT (23 of 29).
Cytotoxic
Therapy
w
ith
H
SCT
in
Pediatric
AM
L
7
s
l
c
c
p
d
P
i
p
p
a
m
r
d
B
(
1
d
i
1
r
t
c
i
d
m
p
i
p
M
c
t
M
9
a
p
f
(
c
t
B
t
M
p
A
c
g
[
B
(
s
B
m
t
c
t
M
a
w
g
(
n
t
c
e
t
P
M
t
s
b
1
c
t
F
a
R
F
D. M. Oliansky et al.8olidation chemotherapy regimens (n  179), each
asting 4-6 weeks. There were no statistically signiﬁ-
ant differences in cytogenetic abnormalities or WBC
ount at diagnosis among the 3 treatment groups.
Ravindranath et al. [13] presented the results of a
rospective, multicenter, randomized study of 649 pe-
iatric (21 yr) patients with AML enrolled in the
ediatric Oncology Group (POG) 8821 trial, compar-
ng auto-BMT, allo-BMT, and chemotherapy. Of 649
atients, 552 (85%) achieved CR1. Eighty-nine (16%)
atients had histocompatible donors and were offered
llo-BMT, and all 89 chose that option. Of the re-
aining 463 patients, 120 (26%) were not eligible for
andomization to chemotherapy only or auto-BMT
ue to insufﬁcient funds (n  64), nonprotocol auto-
MT (n  18), lack of beds at a POG BMT facility
n  14), relapse or death before randomization (n 
1), or other reasons (n  8). In addition, 111 patients
eclined randomization, leaving 232 (68% of 343 el-
gible patients) randomly assigned to auto-BMT (n 
15) or chemotherapy (n  117). Median time from
andomization to marrow harvest for auto-BMT pa-
ients was 49 days (range, 21-106 d). Patients in the
hemotherapy group received 6 courses, each admin-
stered successively at 3-week intervals. The 2 ran-
omized groups had similar distributions of clinical,
orphologic, and cytogenetic features. Figure 2 com-
ares the EFS for the allo-BMT, auto-BMT, and
ntensive chemotherapy groups.
Stevens et al. [14] reported the results of 364
ediatric (15 yr) patients with AML enrolled in the
edical Research Council (MRC) AML10 multi-
enter trial. Children with secondary AML (after prior
reatment or antecedent MDS), DS, or aggressive
DS (RAEB-t) were included. The CR1 rate was
2%. Allo-BMT was recommended for patients with
n HLA-matched sibling donor, and the remaining
atients were randomized between auto-BMT and no
urther treatment. Of those eligible for randomization
n  200), 50% refused randomization, leaving 50
igure 1. DFS from end of induction by diagnostic WBC count
nd matched family donor status for patients with AML in CR1.
eprinted with permission [11].hildren randomized to auto-BMT and 50 to no fur- aher treatment. Of the 50 children allocated to auto-
MT, 44 received a transplant. None of the children in
he no further treatment arm received a BMT in CR1.
edian time from CR1 to transplantation was 155 days.
Amadori et al. [15] presented the results of 173
ediatric (15 yr) patients with newly diagnosed
ML enrolled in a prospective, randomized, multi-
enter (Associazione Italiana Ematologia ed Oncolo-
ia Pediatrica [AIEOP]/Leucemia Acuta Mieloide
LAM] 87) trial comparing chemotherapy, auto-
MT, and allo-BMT. Of 161 evaluable patients, 127
79%) achieved CR1. Patients with an HLA-matched
ibling donor (n  24, 19%) were assigned to allo-
MT, of which 22 received a transplant. Of the re-
aining 103 patients, 72 (70%) were randomized be-
ween auto-BMT (n  35) and a consolidation
hemotherapy regimen (n 37). Of these, 23 went on
o undergo auto-BMT and 32 received chemotherapy.
edian time from CR1 to allo-BMT was 3.2 months
nd from CR1 to auto-BMT was 3.4 months. There
ere no signiﬁcant differences among the 3 treatment
roups in age, French-American-British morphology
FAB) classiﬁcation, WBC count at diagnosis, orga-
omegaly, presence of extramedullary disease, or time
o CR1. Cytogenetic data were not reported.
Pession et al. [16] retrospectively examined out-
omes in 559 pediatric (15 yr) patients with AML
nrolled in 4 AIEOP/LAM (87-92) trials, including
hose in the LAM 87 study discussed above [15].
atients with granulocytic sarcoma, secondary AML,
DS, and DS were excluded from the analysis. Pa-
ients with APL were excluded from the LAM 92
tudy, but included in LAM 87 and LAM 87M. Com-
ined across trials, 78 patients underwent allo-SCT,
10 underwent auto-SCT, and 89 were treated with
hemotherapy alone. Figure 3 compares the DFS for
he allo-SCT, auto-SCT, and chemotherapy groups.
igure 2. EFS from the time of randomization or assignment to
llo-BMT. Reprinted with permission [13].
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Cytotoxic Therapy with HSCT in Pediatric AML 9llogeneic BMT versus Chemotherapy
ith/without Autologous BMT in CR1
The ﬁrst 6 studies [11-16] listed in this section of
able 4 provide the outcomes related to the allo-
MT versus chemotherapy with/without auto-BMT
omparisons from those studies described in Auto-
MT versus Chemotherapy in First CR.
Wells et al. [17] presented the long-term fol-
ow-up of 621 pediatric (21 yr) patients with de novo
ML enrolled in the prospective, multicenter CCG
13 trial comparing allo-BMT with chemotherapy.
xcluded from the trial were infants2 years old with
cute monoblastic leukemia (n  7), patients without
ML (n  12), and others for unspeciﬁed reasons
n  11). Outcome data from diagnosis were based on
he remaining 591 patients, of whom 439 achieved
R1 (74%). There were 113 patients who had an
LA-identical sibling donor or a related donor with a
ingle-antigen mismatch at the HLA-A or HLA-B loci
nd, of these, 92 were assigned to allo-BMT and 83
ent on to receive a transplant. Four patients whose
LA status was unknown (n  3) or who did not have
n HLA-identical sibling donor (n  1) were also
reated with allo-BMT. Median time from end of
nduction to transplantation was 27 days (range, 0-159
). Patients not assigned to transplantation were given
cycles of consolidation chemotherapy consisting of
ifferent regimens (n  343). There were no signiﬁ-
ant differences in baseline patient clinical characteristics
etween the allo-BMT and chemotherapy groups. Cy-
ogenetic data were not reported.
Nesbit et al. [18] evaluated allo-BMT versus che-
otherapy in the multicenter, prospective CCG 251
rial. Of the 508 pediatric ( 21 yr) patients with
ML enrolled in the study, 490 were treated and CR1
igure 3. Estimated probability of 5-yr DFS in patients of
IEOP AML 87-92 studies by postremission treatment: allo-SCT,
uto-SCT, or chemotherapy (CT). Slash indicates the patient without an
vent and with the shortest follow-up. Reprinted with permission [16].as achieved in 381 (78%) patients. Of these, 89 t23%) had an HLA-compatible sibling donor and
ere eligible for allo-BMT, 252 had no matched sib-
ing donor and were eligible for randomization to 2
hemotherapeutic maintenance programs, and for 40
atients the match status was not determined or data
ere not known. No signiﬁcant differences were
ound in the clinical characteristics of the donor versus
o-donor groups. Cytogenetic data were not reported.
Perel et al. [19] and Michel et al. [20] presented
he results of the French, multicenter Leucémie Aiguë
yéloblastique Enfant (LAME) 89/91 trials. Patients
ith secondary AML, FAB M0, MDS, or DS were
xcluded. Of 309 pediatric (20 yr) patients with
ML, 277 achieved CR1 (90%). All 74 patients with
n HLA-identical sibling donor were offered and un-
erwent allo-BMT. Median duration from CR1 to
llo-BMT was 82 days. The remaining patients re-
eived consolidation chemotherapy (n 180) or other
ostremission therapy (n  23).
Lie et al. [21] reported the outcomes for 219
ediatric (18 yr) patients with AML (without DS)
ho were enrolled in the international (Denmark,
inland, Iceland, Norway, and Sweden), multicenter,
ordic Society for Paediatric Haematology and On-
ology (NOPHO)-AML93 trial comparing allo-BMT
ith chemotherapy. Of the 219 patients, 200 (91%)
chieved CR1. Fifty-three (27%) patients underwent
llo-SCT (46 from a matched family donor, 7 from a
atched unrelated donor). An additional 16 patients
nderwent auto-BMT; they were analyzed with the
hemotherapy group (n  147). Figure 4 compares
he DFS for the allo-SCT and chemotherapy groups.
Entz-Werle et al. [22] compared outcomes of allo-
MT versus chemotherapy in 188 pediatric (18 yr)
igure 4. Probability of 7-yr DFS in NOPHO-AML93 according
o postremission therapy in CR1. Reprinted with permission [21].
Table 5. Comparison of Patient Characteristics and Outcomes from Studies Included in the Allo-SCT versus Auto-SCT Section
Reference #
Quality
&
Strength
of
Evidence*
Patient
Population
Patient
Characteristics
Risk
Groups
Number of
Patients by
Study
Group
Upper
Limit
(median)
Age at
Diagnosis
% Treatment
Related
Mortality
Median
Follow-
Up
(Months)
%DFS/
%EFS/
%RFS
(Signif)
Outcome
Defined
% OS
(Signif)
OS
Defined
Allogenic vs Autologous SCT in CR1
[11] 1 Combined 5
CCG
1979-1996
Meta-analysis
Age, WBC, Blast %,
Sex, FAB, Cytogen.
Not Stated Total 1278 (ITT)
Allo 373
Auto 217
<21 yrs
(8.9)
(6.2)
8-yr
17
7
Not
Stated
8-yr DFS
47  5
42  7
(P.075)
Time from CR1
to relapse or
death from
any cause
8-yr
54  5
49  7
(P.03)
Time from CR1
to death from
any cause
[12] 2 CCG Trail 2891
Phase III
Oct 1989 to Apr
1995
Multi-center (236)
US, Canada,
Australia
Age, WBC, FAB,
Cytogen.
Not Stated Total 537 (ITT)
Allo 181
Auto 177
<21 yrs Not Stated
14
5
Not
Stated
(min 4 yr)
8-yr DFS
55  9
42  8
(P.001)
Time from CR1 8-yr
60  9
48  8
(P.002)
Time from CR1
[13] 2 POG Trial 8821
Jun 1988 to Mar
1993
Multi-center
(16)
US
Race, Age, WBC, FAB,
EMD, Induction Response,
DS, Cytogen.
Not Stated Total 321 (ITT)
Allo 89
Auto 115
<21 yrs
(Not
Stated)
Not Stated
Not Stated
15
Not Stated 3-yr EFS
52  8
38  6.4
(P.01)
Time from
randomization
until 1st event
3-yr
Not Stated
40  6.1
(P.007)
Time from
randomization
until death
[27] 2 EBMT Registry
Jan 1987 to Dec
1992
Europe
Retrospective
Age, Sex, FAB,
Cond. Reg,
Time to BMT
Not Stated Total 242
Allo 129
Auto 113
<15 yrs
(10 yrs)
(11 yrs)
4-yr
9  3
8  4
27 mos
20 mos
4-yr LFS
68
47
(P.001)
Time in
continuous CR
Not Stated
[28] 2 ANZCCSG
AML 1&2 Trials
Dec 1986 to
May 1999
Multi-center (8)
Australia, New
Zealand
Age, WBC, FAB, CNS Good
(22.5%)
Standard
(55%)
Poor
(10%)
Not known
(12.5%)
Total 191
Allo 35
Auto 156
<18 yrs
(AML 1
6.3 yr)
(AML 2
7 yr)
3 mos
9
0
AML 1
103 mos
AML 2
42 mo
5-yr DFS
69
52
(Not Signif.)
Time from CR1
to relapse or
death in CR
5-yr
79
63
(Not Signif.)
Time from study
entry to
death or last
follow-up
[29] 2 CCG 2861
Apr 1988 to
Oct 1989
Multi-center
(27) US
Age, WBC, FAB,
EMD, DS
Not Stated Total 74
Allo 16
Auto 58
<21 yrs
(Not
Stated)
<70 days
6
5
31 mos
34 mos
3-yr DFS
55
51  12
(P.92)
Time from
the end of
induction
therapy to last
day of contact
3-yr
54
57  14
(P.56)
Time from
the end of
induction
therapy to last
day of contact
[30] 2 Kyushu-
Yamaguchi
CCSG ANLL93
Jul 1993 to Dec
1997
Japan
ANLL93 Trial
Multi-center
(23)
WBC, FAB, Cytog. Normal vs.
t(8;21),
t(11;19),
t(9;11),
inv(16)
Total 59
Allo 22
Auto 37
<18 yrs
(8.8 yrs)
Not Stated 45 mos 5-yr EFS
70.8  9.3
43  8.1
(P.08)
Time from DX
to an event
(failure to reach
CR1, death
during induction,
death during CR,
or relapse)
Not
Stated
[31] 2 Kousei-Shou
ANLL91
Feb 1986 to
May 1998
Single Center
Japan
Retrospective
WBC, FAB Not Stated Total 52
Allo 31
Auto 21
<16 yrs
(7 yrs)
Not Stated
10
0
70 mos 5-yr DFS
84
81
(Not Signif.)
Time from BMT
to relapse
or death
Not
Stated
D
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Table 5. Continued
Reference #
Quality
&
Strength
of
Evidence*
Patient
Population
Patient
Characteristics
Risk
Groups
Number of
Patients by
Study
Group
Upper
Limit
(median)
Age at
Diagnosis
% Treatment
Related
Mortality
Median
Follow-
Up
(Months)
%DFS/
%EFS/
%RFS
(Signif)
Outcome
Defined
% OS
(Signif)
OS
Defined
[32] 2 AML-88 Trial
Apr 1988 to
May 2001
Single Center
Spain
High Risk Pts.
Age, Sex, WBC,
FAB, Cytogen,
>1 Induction
Cycle
Unfavor. vs
Others
Total 48
Allo 17
Auto 31
<15 yrs
(5 yrs)
Not Stated
5.9
3.2
8-yr EFS
74.5
74.2
(Not Signif.)
Time from DX to
relapse, death
from any cause,
or last follow-up
Not
Stated
[34] 2 AIEOP
Jan 1985 to Dec
1998
Multi-center (19)
Italy
Retrospective
Not Stated Not Stated Total 278
Allo 115:
Sibling donor 103
Other donor 12
Auto 163
<18 yrs
(Not
Stated)
Not Stated Not
Stated
5-yr EFS
63.1  5.3
48.6  14.8
46.6  4.4
(Not Stated)
Time to relapse
or death from
any cause,
whichever
occurs first
Not
Stated
[35] 2 MRC10
protocol
1992 to 2002
Single Center
Turkey
Retrospective
Age, Sex, FAB Not Stated Total 67
Allo 31
Auto SCT:
Auto-BMT 20
Auto PBSCT 16
<17 yrs
(8 yrs)
Not Stated
19
5
62 mos
70 mos
36 mos
5-yr DFS
61
50
75
(Allo vs
Auto BMT
P.48;
Allo vs
PBSCT
P.067)
Time from DX
(event not
defined)
Not
Stated
Allogeneic vs Autologous SCT in CR2
[36] 2 LAME 89/91
Dec 1988 to
Dec 1998
Multicenter (19)
France
Age, Sex, WBC,
FAB, CR1
Duration,
Cytogen.
Favorable†
vs. Other
Total 53
Matched Allo 12
Unrelated Allo
16
Auto 25
<20 yrs
(Not
Stated)
Not Stated
16
31
4
65 mo 5-yr DFS
60
44
47
(Not Signif.)
Time from CR2
to attainment
of event (not
defined)
Not
Stated
[27] 2 EBMT Registry
Jan 1987 to Dec
1992
Europe
Retrospective
Age, Gender, FAB,
Time to BMT,
CR1 Duration
Not Stated Total 52
Allo 17
Auto 35
<15 yrs
(9 yrs)
(10 yrs)
4-yr
18
12
38 mos
33 mos
4-yr LFS
39
40
(Not Signif.)
Time in
continuous CR
Not
Stated
[34] 2 AIEOP
Jan 1985 to Dec
1998
Multi-center (19)
Italy
Retrospective
Not Stated Not Stated Total 69
Allo 16:
Sibling donor 11
Other donor 5
Auto 53
<18 yrs
(Not
Stated)
Not Stated Not
Stated
5-yr EFS
63.1  5.3
48.6  14.8
46.6  4.4
(Not Stated)
Time to relapse
or death from
any cause,
whichever
occurs first
Not
Stated
ANLL indicates acute nonlymphocytic leukemia; ANZCCSG, Australian and New Zealand Children’s Cancer Study Group; EBMT, European Group for Blood and Marrow Transplantation; LFS, leukemia-free survival; ITT, intent to treat; DX, diagnosis; Chemo,
chemotherapy; CCG, Children’s Cancer Group; POG, Pediatric Oncology Group; MRC, Medical Research Council; AIEOP, Associazione Italiana Ematologia ed Oncologia Pediatrica; LAM, Leucemia Acuta Mieloide; NOPHO, Nordic Society for Paediatric
Haematology and Oncology; LAME, Leucémie Aiguë Myéloblastique Enfant; EORTC, European Organization of Research and Treatment of Cancer; TPOG, Taiwan Pediatric Oncology Group; RFS, relapse-free survival; WBC count, WBC count at diagnosis;
EMD, extramedullary disease; SR, standard risk; HR, high risk.
*Quality and strength of evidence deﬁnitions are listed in Table 1.
†Favorable  t(8;21), t(15;17), inv(16).
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D. M. Oliansky et al.12atients with AML enrolled in the prospective, mul-
icenter European Organization of Research and
reatment of Cancer (EORTC) 58921 trial. Patients
ith DS or APL were excluded. Of 145 patients (82%)
ho achieved CR1, 39 had an HLA-identical sibling
onor (donor group), 33 (85%) of whom underwent
llo-BMT. One hundred six patients were assigned to
he no-donor (chemotherapy) group, of whom 3 un-
erwent allo-BMT in CR1, 17 underwent allo-BMT
n second CR (CR2), and 4 underwent auto-BMT in
R2.
Liang et al. [23] reported the outcomes of 117
ediatric (18 yr) patients with AML enrolled in the
rospective, multicenter, Taiwan Pediatric Oncology
roup (TPOG)-AML-97A trial comparing SCT with
hemotherapy. Ninety percent (n  105) of patients
ttained CR1. SCT was performed “as feasible,” with
9 patients undergoing some form of SCT (allo-
MT, n 17; allo-PBSCT, n 6; auto-BMT, n 2;
uto-PBSCT, n  4) and 76 patients receiving che-
otherapy only. Median time from CR1 to transplan-
ation was not stated.
Dahl et al. [24] presented the results of a prospec-
ive, multicenter trial (AML-80) of 87 pediatric (20
r) patients with AML comparing allo-BMT with che-
otherapy. Sixty-ﬁve patients (75%) achieved CR1.
atients without donors (n  42) were assigned to
eceive intensive consolidation chemotherapy and 19
atients with HLA-compatible donors were recom-
ended to undergo allo-BMT, 15 of whom received a
ransplant. Median time from CR1 to allo-BMT was
5 day.
Lange et al. [25] reported the outcomes of 93
ediatric (20 yr) patients with AML enrolled in a
rospective, multicenter, CCG 2941 trial comparing
llo-BMT with chemotherapy. Patients with DS or
PL were excluded. Fifty-seven (61%) patients
chieved CR1 after induction therapy. Fourteen pa-
ients then underwent matched related allo-BMT and
3 received chemotherapy.
llogeneic BMT versus Chemotherapy in CR2
Wells et al. [26] presented the outcomes of allo-
MT versus chemotherapy only for 101 pediatric
21 yr) patients with refractory (16%) or ﬁrst relapse
84%) AML enrolled in the CCG 2951 trial. Of the
atients with relapsed AML (n  85), 73% had a CR1
uration 12 month and 27% had a CR1 12
onths. After salvage induction and/or intensiﬁca-
ion, 13 patients received further consolidation che-
otherapy and 35 patients underwent allo-BMT from
variety of donor sources (30 from unrelated, 4 from
elated, 1 from unknown donors). Twelve of the pa-
ients who underwent allo-BMT received a transplant
fter reinduction and 23 underwent allo-BMT after
ntensiﬁcation. mUTOLOGOUS SCT VERSUS ALLOGENEIC SCT
The following text describes the study design of
ach of the 12 articles included in this section. Table
presents a summary of the outcomes for each study.
he highest quality studies are presented ﬁrst in the
ext and table; studies of equal quality are presented in
escending order by sample size. Of the 12 studies
nvestigating allo-SCT versus auto-SCT, 3 indicated a
igniﬁcant difference in DFS (or EFS) between the 2
reatment groups, and 3 stated a signiﬁcant difference
n OS.
irst CR
The ﬁrst 3 studies listed in Table 5 [11-13] were
escribed under Auto-BMT versus Chemotherapy in
R1. The outcomes related to the allo- versus auto-
MT comparisons from those studies are presented in
his section of Table 5.
Gorin et al. [27] presented a retrospective study on
he outcomes of auto-BMT versus allo-BMT in 242
ediatric (15 yr) patients with AML reported to the
cute leukemia European Group for Blood and Mar-
ow Transplantation (EBMT) registry after transplan-
ation in CR1 by the EBMT. Of the 242 patients, 129
nderwent allo-BMT and 113 underwent auto-BMT.
he clinical characteristics of the treatment groups
ere similar, with 2 exceptions: more patients after
llo-BMT received TBI-containing conditioning reg-
mens (59% versus 43%, P  .01) and more under-
ent transplantation earlier (77 versus 131 week, P 
0001) compared with patients who underwent auto-
MT. Cytogenetic data were not reported.
O’Brien et al. [28] reported the results for 280
ediatric (18 yr) patients with AML enrolled in 2
onsecutive Australian and New Zealand Children’s
ancer Study Group (ANZCCSG) AML clinical tri-
ls (AML1 and AML2) comparing the outcomes of
uto-BMT versus allo-BMT. Patients with APL (n 
2, 12%, in the AML1 trial; n  19, 12%, in the
ML2 trial) were included, whereas patients with
DS, secondary AML, and DS-related leukemic dis-
rders were excluded from the analysis. Eight patients
ied before treatment and 10 did not receive protocol
reatment. Of the 262 evaluable patients, 242 (92%)
chieved CR1. Fifty-two (22%) patients did not pro-
eed to BMT (relapse or death, n  36; removal from
tudy, n  5; preference or refusal, n  5; other, n 
). Thirty-ﬁve patients underwent allo-BMT (33
atched sibling, 1 matched related cord blood, 1
atched unrelated) and patients without an HLA-
dentical sibling underwent auto-BMT (n  156).
edian times from diagnosis to BMT were 6 and 5
onths for the AML1 and AML2 trials, respectively.
atients were classiﬁed as having good (n  59, t(8;
1), t(15;17), inv(16), or FAB type M3), poor (n  26,
onosomy 5 or 7, deletions or abnormalities of chro-
m
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Cytotoxic Therapy with HSCT in Pediatric AML 13osomes 5 or 3, or complex karyotypes), or standard
n  144, all remaining patients) cytogenetic risk.
here were no major differences between patients in
he AML1 and AML2 trials in terms of age, WBC
ount at diagnosis, CNS disease, FAB classiﬁcation, or
ytogenetic risk groups.
Woods et al. [29] compared the effect of auto-
MT versus allo-BMT in 142 pediatric (21 yr) pa-
ients with AML enrolled in the CCG 2861 trial.
atients with Ph chromosome CML, chronic my-
lomonocytic leukemia, juvenile CML, or Fanconi
nemia were excluded from the trial. Children with
S were included but assigned only to auto-BMT.
verall, 108 (76%) patients achieved CR1 and were
ligible for BMT; of these, 28 withdrew from study, 2
elapsed before BMT, and 3 patients had unknown
MT status. Of the remaining 75 patients, 58 under-
ent 4-hydroperoxycyclophosphamide purged auto-
MT, 16 underwent an HLA-identical sibling donor
llo-BMT, and 1, who died from complications and
as not included in further analyses, underwent un-
elated donor allo-BMT. Median time from CR1 to
MT was 43 days. Cytogenetic data were not re-
orted.
Matsuzaki et al. [30] compared the outcomes of
uto-BMT versus allo-BMT in 64 pediatric (18 yr)
atients with AML enrolled in the Kyushu-Yamagu-
hi Children’s Cancer Study Group ANLL93 trial.
atients with DS or APL were excluded from the trial.
verall, 59 (92%) patients achieved CR1, and of
hese, 22 (37%) with an HLA-identical sibling were
ssigned to allo-BMT and 18 actually received a trans-
lant. Of the 37 patients who did not undergo allo-
MT, 11 underwent auto-PBSCT, 6 auto-BMT, 6
hemotherapy alone, 3 unrelated allo-BMT, 1 CBT
rom a sibling, and 10 patients relapsed or died before
ransplantation. Median times from diagnosis to trans-
lantation were 7.4 months for auto-PBSCT and 8.6
onth for auto-BMT (allo-BMT not stated). There
ere no differences in clinical or cytogenetic charac-
eristics at time of diagnosis among patients who un-
erwent allo-BMT, auto-BMT, and auto-PBSCT.
Matsuyama et al. [31] provided a retrospective
nalysis of 52 pediatric (16 yr) patients with AML
reated with allo-BMT or auto-BMT according to the
ousei-Shou ANLL91 protocol at a single institution
n Japan. All patients (100%) achieved CR1, after
hich 31 (60%) underwent allo-BMT (24 sibling, 4
amily, 1 HLA single-antigen mismatched family, 2
nrelated donor) and 21 (40%) underwent auto-BMT.
edian times between diagnosis and transplantation
ere 6 months for allo-BMT and 7 months for auto-
MT. Cytogenetic data were not reported.
Ortega et al. [32] compared the outcomes of auto-
MT versus allo-BMT in 50 pediatric (15 yr) pa-
ients with AML enrolled in the prospective, single-
nstitution AML 88 trial and identiﬁed as high risk tccording to the Berlin-Frankfurt-Münster (BFM)
riteria [33] based on morphology, cytogenetics, and
esponse to induction treatment. CR1 was achieved in
6 patients (92%) and partial remission was attained in
patients. Of the 48 responding patients, 17 had an
LA-identical sibling donor and all underwent allo-
MT. The remaining 31 had no donor and under-
ent auto-BMT (purged, n  24; purged and un-
urged or unpurged alone, n  7). Clinical
haracteristics of the 2 groups were similar. Median
ime from CR1 to BMT was 3 months.
Pession et al. [34] retrospectively examined the
utcomes of allo-BMT and auto-SCT in 278 pediatric
18 yr) patients with AML in CR1 treated at 19
IEOP centers. Stem cell sources for patients under-
oing auto-SCT (n  163) included BM, PB, or a
ombination of PB and BM. Of the 115 who under-
ent allo-BMT, 103 had sibling donors and 12 had
atched or partially matched unrelated donors. Cy-
ogenetic data were not reported.
Anak et al. [35] provided the results of 92 pediatric
17 yr) patients with AML treated according to the
RC 10 protocol at a single center in Turkey. Five
atients with APL were excluded. Of the 78 (90%)
atients who achieved CR1, 31 were assigned to allo-
MT if an HLA matched sibling was available, 36
ere randomized to auto-SCT (20 BMT, 16 PBSCT),
nd 11 dropped out or received chemotherapy. Me-
ian times to transplantation after diagnosis were 6,
0, and 6 months in the allo-BMT, auto-BMT, and
uto-PBSCT groups, respectively. Cytogenetic data
ere not reported.
econd CR
Aladjidi et al. [36] presented the outcomes of 106
ediatric (20 yr) patients with relapsed AML in the
rench prospective LAME 89/91 protocol. Median
uration of CR1 was 10 months. Ten patients (9%)
eceived only palliative treatment. Reinduction was
ttempted in 96 patients, and CR2 was attained in 68
71%). Of these, 53 (78%) patients underwent auto-
MT (n 25), matched sibling donor allo-BMT (n
2), or alternative allo-SCT (n  16; 11 unrelated
onors, 3 HLA-mismatched familial donors, and 2
nrelated cord blood cells). For 9 children this was a
econd transplantation.
The retrospective EBMT study by Gorin et al.
27] presented under Allo-SCT versus Auto-SCT in
R1 also examined the outcomes of 52 pediatric (15
r) patients with AML who underwent transplantation
n CR2 and received an auto-BM transplant (n  35)
r an allo-BM transplant (n  17). Cytogenetic data
ere not reported.
Pession et al. [34], whose study was also presented
nder Allo-SCT versus Auto-SCT in CR1, examined
he outcomes of 69 pediatric (18 yr) patients who
Table 6. Comparison of Patient Characteristics and Outcomes from Studies Included in the Autologous Transplantation Section
Reference
No.
Quality and
Strength of
Evidence* Patient Population
Patient
Characteristics Risk Groups
No. of Patients by
Study Group
Upper Limit
(Median)
Age at DX %TRM
Median Follow-up
(mo)
%DFS/
%RFS/
%EFS/
%LFS Outcome Defined %OS OS Defined
Auto-SCT (purged and unpurged auto-SCT)
37 2 ABMTR, 1989-
1998, US,
Canada, Central
and South
America,
retrospective
Age, sex, race,
WBC count,
FAB, CNS,
KPS, disease
status, time to
CR1,
cytogenetics
Good† (13%)
Intermediate
(52%)
Poor (6%)
Not known
(29%)
Auto-BMT 219 <21 yr
(10 yr)
Not stated 80 mo 3-yr LFS
54
(95% CI,
47–60)
Time in
continuous CR
3-yr
62
(95% CI,
54–68)
Not stated
38 2 AML-91 protocol,
2-CDA,
induction
therapy, June
1991-December
1996, 2 US
centers
Age, sex, WBC
count,
hemoglobin,
platelets, FAB,
cytogenetics
Not stated Auto-BMT 40 <19 yr
(4.9 yr)
Not stated Not stated Overall
5-yr. EFS
40  8
Time from enroll.
to relapse,
disease
progress, death
from any cause,
or last follow-
up
Not stated
Unpurged auto-SCT
39 2 January 1997-May
2002, single
center, Korea
Age, sex, FAB,
cytogenetics
Poor‡ (11%)
Good (36%)
Auto-PBSCT 28
(BCVAC
conditioning)
<15 yr (not
stated)
Not stated
0
30.5 mo Overall
EFS
71.4  8.5
Time from DX to
first event
(relapse or
therapy-related
death)
Not stated
40 2 JCSG/PBSCT,
CCLSG 9205,
and CCLSG
9411, May 1989-
October 1996,
multicenter,
Japan,
retrospective
Age, WBC
count, FAB,
time to CR1
Not stated Auto-PBSCT 24 <18 yr
(8 yr)
Not stated
4
55 mo 5-yr DFS
49
(95% CI,
39–60)
Time from SCT
to relapse or
death
5-yr
53
(95% CI,
41–64)
Time from
SCT to
death
41 2 Auto-BMT,
November 1984-
January 1991,
single center,
Australia
Age, sex, WBC
count, EMD,
cytogenetics
Not stated Auto-BMT 24
(high-dose
melphalan
conditioning)
<16 yr
(7 yr)
Not stated
0
57 mo 5-yr EFS
87
(95% CI,
71–100)
Time from BMT
to failed CR,
relapse, or
death from any
cause
5-yr
92
(95% CI,
76–100)
Time from
BMT to
death
from any
cause
Purged auto-SCT
42 2 AIEOP, auto-BMT,
January 1988-
October 1998,
multicenter (6),
Italy
Age, sex, FAB,
WBC count,
cytogenetics
Poor§ (21%)
Standard (79%)
Auto-BMT 53
(TBI and
melphalan
conditioning)
<18 yr
(6 yr)
1 yr
4
40 mo 5-yr DFS
68
(95% CI,
55–81)
Time from BMT
to relapse or
death in
remission from
any cause
5-yr
78
(95% CI,
65–90)
Not stated
D
.
M
.
O
liansky
et
al.
14
u
c
a
m
t
A
t
q
t
s
o
p
a
T
v
c
S
A
t
q
t
d
s
1
r
w
r
s
a
a
a
s
C
m
f
b
c
t
a
c
c
B
nbl
e
6.
C
on
tin
ue
d
er
en
ce
N
o
.
Q
ua
lit
y
an
d
S
tr
en
gt
h
o
f
E
vi
de
nc
e*
P
at
ie
nt
P
o
pu
la
ti
o
n
P
at
ie
nt
C
ha
ra
ct
er
is
ti
cs
R
is
k
G
ro
up
s
N
o
.
o
f
P
at
ie
nt
s
by
S
tu
dy
G
ro
up
U
pp
er
L
im
it
(M
ed
ia
n)
A
ge
at
D
X
%
T
R
M
M
ed
ia
n
F
o
llo
w
-u
p
(m
o
)
%
D
F
S
/
%
R
F
S
/
%
E
F
S
/
%
L
F
S
O
ut
co
m
e
D
efi
ne
d
%
O
S
O
S
D
efi
ne
d
o
-B
M
T
vs
au
to
-P
B
S
C
T
2
K
yu
sh
u-
Y
am
ag
uc
hi
C
C
S
G
,
A
N
L
L
93
tr
ia
l,
m
ul
ti
ce
nt
er
(2
3)
,
Ja
pa
n
W
B
C
co
un
t,
F
A
B
,
cy
to
ge
ne
ti
cs
N
o
rm
al
t(
8;
21
),
t(
11
;1
9)
,
t(
9;
11
),
in
v(
16
)
T
o
ta
l
17
A
ut
o
-B
M
T
6
A
ut
o
-P
B
S
C
T
11
<
18
yr
(8
.8
yr
)
N
o
t
st
at
ed
45
m
o
5-
yr
E
F
S
83
.3
41
.6
(N
o
t
S
ig
ni
f.)
T
im
e
fr
o
m
D
X
to
fi
rs
t
ev
en
t
(f
ai
le
d
C
R
,
de
at
h
du
ri
ng
in
du
ct
io
n
o
r
C
R
,
o
r
re
la
ps
e)
N
o
t
st
at
ed
1
M
R
C
10
pr
o
to
co
l,
19
92
-2
00
2,
si
ng
le
ce
nt
er
,
T
ur
ke
y
A
ge
,
se
x,
F
A
B
N
o
t
st
at
ed
T
o
ta
l
36
R
an
do
m
iz
ed
au
to
-
B
M
T
20
R
an
do
m
iz
ed
au
to
-
P
B
S
C
T
16
<
17
yr
(8
yr
)
N
o
t
st
at
ed
0 5
70
m
o
36
m
o
5-
yr
D
F
S
50 75 (P

.0
46
)
T
im
e
fr
o
m
D
X
(e
ve
nt
no
t
de
fi
ne
d)
N
o
t
st
at
ed
L
L
,a
cu
te
no
n-
ly
m
ph
oc
yt
ic
le
uk
em
ia
;A
B
M
T
R
,A
ut
ol
og
ou
s
B
lo
od
an
d
M
ar
ro
w
T
ra
ns
pl
an
t
R
eg
is
tr
y;
L
FS
,l
eu
ke
m
ia
-f
re
e
su
rv
iv
al
;K
P
S,
K
ar
no
fs
ky
pe
rf
or
m
an
ce
st
at
us
;I
T
T
,i
nt
en
t
to
tr
ea
t;
D
X
,d
ia
gn
os
is
;C
he
m
o,
ch
em
ot
he
ra
py
;C
C
G
,C
hi
ld
re
n’
s
C
an
ce
r
G
ro
up
;
P
O
G
,P
ed
ia
tr
ic
O
nc
ol
og
y
G
ro
up
;M
R
C
,M
ed
ic
al
R
es
ea
rc
h
C
ou
nc
il;
A
IE
O
P
,A
ss
oc
ia
zi
on
e
It
al
ia
na
E
m
at
ol
og
ia
ed
O
nc
ol
og
ia
P
ed
ia
tr
ic
a;
L
A
M
,L
eu
ce
m
ia
A
cu
ta
M
ie
lo
id
e;
N
O
P
H
O
,N
or
di
c
So
ci
et
y
fo
r
P
ae
di
at
ri
c
H
ae
m
at
ol
og
y
an
d
O
nc
ol
og
y;
L
A
M
E
,L
eu
cé
m
ie
A
ig
uë
M
yé
lo
bl
as
tiq
ue
E
nf
an
t;
E
O
R
T
C
,E
ur
op
ea
n
O
rg
an
iz
at
io
n
of
R
es
ea
rc
h
an
d
T
re
at
m
en
t
of
C
an
ce
r;
T
P
O
G
,T
ai
w
an
P
ed
ia
tr
ic
O
nc
ol
og
y
G
ro
up
;R
FS
,r
el
ap
se
-f
re
e
su
rv
iv
al
;W
B
C
co
un
t,
W
B
C
co
un
t
at
di
ag
no
si
s;
E
M
D
,e
xt
ra
m
ed
ul
la
ry
di
se
as
e;
SR
,s
ta
nd
ar
d
ri
sk
;H
R
,h
ig
h
ri
sk
.
al
ity
an
d
st
re
ng
th
of
ev
id
en
ce
de
ﬁn
iti
on
s
ar
e
lis
te
d
in
T
ab
le
1.
oo
d
pr
og
no
si
s
in
di
ca
te
s
16
q,
t(
8:
21
);
in
te
rm
ed
ia
te
,
8,

21
,t
(1
;7
),
t(
6;
9)
,t
(8
;1
6)
,n
or
m
al
cy
to
ge
ne
tic
s;
po
or
,
5/
5q

,
7/
7q

,
20
/2
0q

,3
q,
11
q,
t(
5;
7)
,t
(9
;2
2)
,c
om
pl
ex
ka
ry
ot
yp
es
.
oo
d
in
di
ca
te
s
t(
8;
21
),
in
v(
16
);
po
or
,
2
co
ur
se
s
of
in
du
ct
io
n,
W
B
C
co
un
t

10
0
00
0
at
di
ag
no
si
s.
an
da
rd
in
di
ca
te
s
no
rm
al
ka
ry
ot
yp
e,
ot
he
r
cy
to
ge
ne
tic
ab
no
rm
al
iti
es
,u
nk
no
w
n
cy
to
ge
ne
tic
da
ta
;p
oo
r,
m
on
os
om
y
5
or
7,
11
q,
t(
6;
9)
,t
(8
;1
6)
,t
(1
/2
2)
.
Cytotoxic Therapy with HSCT in Pediatric AML 15nderwent transplantation in CR2. Of these, 53 re-
eived an auto-BM transplant, and of 16 who received
llo-BM transplants, 11 had sibling donors and 5 had
atched or partially matched unrelated donors. Cy-
ogenetic data were not reported.
UTOLOGOUS SCT
The data from the 8 auto-SCT studies included in
his section are presented in Table 6. The highest
uality studies are presented ﬁrst in each section of the
able; studies of equal quality are presented in de-
cending order by sample size.
Of the 8 auto-SCT studies, 6 presented the results
f single-arm, noncomparative studies examining
urged and unpurged auto-SCT (2 studies), unpurged
uto-SCT (3 studies), and purged auto-SCT (1 study).
he remaining 2 studies in this section [30,35], pre-
iously described under Auto-SCT versus Allo-SCT,
ompared outcomes from auto-BMT versus auto-PB-
CT.
LLOGENEIC SCT
The data from the 9 allo-SCT studies included in
his section are presented in Table 7. The highest
uality studies are presented ﬁrst in each subsection of
he table; studies of equal quality are presented in
escending order by sample size.
Of the 9 allo-SCT studies, 1 was a comparative
tudy [43] that presented the outcomes of related (n
2) versus unrelated (n  20) donor allo-SCT in a
etrospective study of 32 pediatric (6 yr) patients
ith AML reported to the Eurocord Registry. The
emaining 8 allo-SCT studies presented the results of
ingle-arm, noncomparative studies examining related
nd unrelated allo-SCT in CR2 (1 study), related
llo-SCT (4 studies), unrelated allo-SCT (1 study),
nd T cell depleted (or partially depleted) allo-SCT (2
tudies).
ONDITIONING REGIMENS
Two comparative studies of conditioning regi-
ens are summarized in this section; neither study
ound statistically signiﬁcant differences in outcomes
etween conditioning regimens.
Michel et al. [52] retrospectively analyzed the out-
omes of 74 pediatric (16 yr) patients with AML
reated with HLA-identical related allo-SCT in CR1
nd reported to a French BMT registry. Conditioning
onsisted of busulfan (Bu; oral) plus 120 mg/kg of
yclophosphamide (Cy; Bu  Cy 120 group, n  23),
u (oral) plus 200 mg/kg Cy (Bu  Cy 200 group,
 19), or based on TBI, usually in combination with120 mg/kg Cy (TBI group, n  32). Median timesTa Re
f
A
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30 35 A
N *Q
u
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Table 7. Comparison of Patient Characteristics and Outcomes from Studies Included in the Allogeneic Transplantation Section
Reference
No.
Quality and
Strength of
Evidence* Patient Population
Patient
Characteristics Risk Groups
No. of Patients by
Study Group
Upper Limit
(Median)
Age at DX %TRM Median Follow-up
%DFS/
%RFS/
%EFS/
%LFS Outcome Defined %OS OS Defined
Related vs unrelated allo-SCT
43 2 Eurocord Group,
April 1990-
December 1997,
multicenter
(41),
retrospective
Age, weight, sex,
donor, disease
status,
cytogenetics
Good (72%)
Poor (28%)
Allo UCBT 32
Related 12
Unrelated 20
Overall
<15 yr
(5.5 yr)
(AML only
not
stated)
1 yr
18
42
Overall
34 mo
14 mo
(AML only not
stated)
2-yr EFS
58
32
(P.19)
Time from CBT
to relapse or
death in CR
Not
Stated
Allo-SCT (related and unrelated)
44 2 CR2, relapsed, or
refractory
patients, January
1990-December
1999, single US
center,
retrospective
Age, sex, FAB,
EMD, CR1
duration,
disease status,
disease
burden,
cytogenetics
Not stated Allo 58 (related
and unrelated)
<18 yr
(7.4 yr)
<100 d
16
9 yr 5-yr DFS
24
(95% CI,
14–36)
Time to relapse
or death (start
point not
defined)
Not
Stated
Related allo-SCT
45 2 CCG 2891,
October 1989-
April 1995,
multicenter, US
Sex, FAB,
cytogenetics,
splenomegaly,
hepatosplenomegaly,
donor,
induction
Not stated Related allo 150 <21 yr (not
stated)
Not stated Not stated 6-yr DFS
57
(95% CI,
48–65)
Time from CR1
to relapse or
death from any
cause
6-yr
67
(95% CI,
58–74)
Time from
CR1 to
death
46 2 June 1979-
December 1990,
multicenter
(13), France,
retrospective
Age, WBC, FAB,
CMV,
conditioning
regimen, time
from DX to
BMT
Not stated Related Allo 74 <16 yr
(10 yr)
<18 mo
22
46 mo 6-yr EFS
59  12
Time from CR1
to relapse or
death from any
cause
6-yr
62  11
Not stated
47 2 AIEOP, August
1980-June 1990,
multicenter
(11), Italy,
retrospective
Sex, age, WBC
count, FAB,
induction,
cytogenetics
Not stated Related allo 59 <15 yr
(9 yr)
Not stated
33 (1980-1987)
4 (1988-1990)
59 mo 5-yr RFS
57.8
(95% CI,
43.7–71.9)
Time from SCT
to relapse,
progress, or
death in CR
5-yr
61.3
(95% CI,
47.3–75.2)
Not stated
48 2 January 1985-
August 2000,
single US
center,
retrospective
Sex, age, WBC
count, FAB,
induction,
cytogenetics
Not stated Related allo 41 <18 yr
(11 yr)
Not stated for
children only
5.5 yr 7-yr EFS
63
Time from SCT
to graft
rejection,
relapse, or
death
Not
Stated
Unrelated allo-SCT
49 2 Eurocord Group,
1994-March
2002,
multicenter
(49),
retrospective
Age, WBC, FAB,
CNS,
cytogenetics
Abnormal
Normal
Allo UCBT 95 <15 yr
(4.8 yr)
Day 100
20  4
31 mo 2-yr LFS
42  5
Time from CBT
to relapse or
death in CR
2-yr
49  5
Time from
CBT to
death
from any
cause
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Cytotoxic Therapy with HSCT in Pediatric AML 17rom CR1 to SCT for the 3 conditioning groups were
1  14, 75  16, and 96  19 days, respectively (not
igniﬁcantly different). The mean age of patients was
igniﬁcantly older in the TBI group than in the Bu 
y 120 (P  .01) and Bu  Cy 200 (P  .01) groups.
ytogenetic data were not reported. There was lower
FS in the Bu  Cy 120 group (46  24%, P  .07)
han in the Bu  Cy 200 (82  18%) and TBI (80 
4%) groups at median follow-ups of 28, 31, and 48
onths, respectively; however, this was not statisti-
ally different. Probabilities of TRM occurring while
atients were in CR were 0  11%, 5  11%, and
0  11%, respectively, for the 3 groups.
Ayas et al. [53] retrospectively compared the out-
omes of 66 pediatric (15 yr) patients with AML in
R1 at a single institution who underwent HLA-
atched related allo-BMT after conditioning with Bu
oral)  Cy (n  18) or Bu (oral)  Cy  etoposide
n  48). Median time from CR1 to BMT and cyto-
enetic data were not reported. Patient clinical char-
cteristics were similar in both groups. There was no
igniﬁcant difference in 5-year OS (50% versus
3.3%, P  .09) or EFS (35.9% versus 53.9%, P 
38) between the Bu  Cy and Bu  Cy  etoposide
roups.
ECOND BMT AFTER FAILED FIRST BMT
Two single-arm, noncomparative studies of sec-
nd BMT after a failed ﬁrst BMT are summarized in
he following text.
Meshinchi et al. [54] reported outcomes for 25
ediatric (18 yr) patients with AML who underwent
llo-SCT (12 HLA-matched related, 9 HLA-mis-
atched related, 4 HLA minor-mismatched unre-
ated) for recurrent disease after a prior auto-SCT
n 11) or allo-SCT (n 14). Median time from ﬁrst
CT to relapse was 6.2 months. Median time between
rst and second SCT was 9.6 months. Cytogenetic
ata were not reported. OS at 10 year after the second
ransplantation was 48%, DFS was 44%, and TRM at
ay 100 was 12%. DFS for patients who underwent
econd transplantation in remission was higher than
hat for those who underwent transplantation while in
elapse (70% versus 27%, P  .05).
The following study consists of25 patients but is
ncluded due to the paucity of data in this section.
ale et al. [55] retrospectively examined the outcomes
f 23 pediatric (17 yr) patients (87% de novo AML)
t a single institution who underwent allo-BMT (9
LA-matched related, 14 HLA-matched unrelated)
or recurrent disease after a prior auto-BMT. Median
ime to disease recurrence after auto-BMT was 161
ays. Median time between auto-BMT and allo-BMT
as 291 days. Cytogenetic data were not reported.
FS at 4 years was 39% and the cumulative incidenceof TRM at 2 years was 34.8%.Ta Re
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D. M. Oliansky et al.18able 8. Prognostic Factors Related to Outcome (DFS, EFS, and/or OS), Regardless of Treatment
Reference No./Trial Univariate Analysis Multivariate Analysis
2/CCG 213 Poor 7-yr OS:
Platelets <20 000/L at diagnosis (P  .047)
Hepatomegaly present (P  .004)
Day 14 BM >15% blasts (P  .018)
Better 7-yr OS:
Cytogenetics: abnormal chromosome 16 (P 
.001)
Better 7-yr OS:
Cytogenetics: abnormal chromosome 16 (P 
.001)
Poor 7-yr OS:
Hepatomegaly present (P  .005)
Day 14 BM >15% blasts (P  .024)
Not significant for OS:
Gender, age, race, WBC count diagnosis,
hemoglobin, FAB, MDS, splenomegaly,
chloroma, CNS at diagnosis, Auer rods
1/5 CCG trials combined Not reported Not significant for 8-yr OS:
WBC count (P  .065)
FAB (P  .059)
Better 8-yr DFS:
WBC count <50 000/L (P < .001)
3/NOPHO-AML93,
multivariate; 21/
NOPHO-AML93,
univariate
Better 7-yr EFS:
Induction response good* (P < .01)
WBC count <50 000/L at diagnosis (P < .01)
Age <10 yr (P  .04)
FAB  M1 (P  .03)
Cytogenetics t(9;11) (P < .01)
Having t(9;11), t(8;21), or abnormal
chromosome 16 vs not having (P  .02)
Better 5-yr EFS:
Induction response good* (P < .01)
WBC count <50 000/L at diagnosis (P  .02)
Age <10 yr (P  .05)
2 /EORTC-58921 Not reported Better 5-yr OS:
Cytogenetics favorable [inv(16) or t(8;21)] (P
 .008)
Not significant for 5-yr OS and EFS:
Age (P value not stated)
WBC count (P value not stated)
4/MRC AML 10 and 12 Not reported Poor 5-yr OS:
Older age (continuous variable) (P  .02)
WBC count higher at diagnosis (continuous
variable; P < .001)
FAB  M5 (P  .02)
Cytogenetics poor risk (P < .001)
Better 5-yr DFS:
WBC lower at diagnosis (continuous variable;
P < .001)
FAB M5 (P  .03)
Day 14 BM <15% blasts (P < .001)
MRC risk group: good† (P < .001)
Not significant for 5-yr DFS:
Age (continuous variable; P  .06)
Better 5-yr EFS:
Younger age (continuous variable; P  .02)
WBC count lower at diagnosis (continuous
variable; P < .001)
FAB M5 (P  .01)
Cytogenetics: favorable risk (P < .001)
4/MRC AML 10 Poor 7-yr OS:
MRC risk group poor† (P < .0001)
Not reported
Poor 7-yr DFS:
MRC risk group poor† (P < .0001)
5/MRC AML 10 and 12 Poor 5-yr OS:
Status after 1 course resistant disease (blasts
>15%; P  .0001)
Not reported
MRC risk group: poor† (P < .0001)
Cytogenetics: adverse risk (P  .0007)
Poor 5-yr DFS:
MRC risk group: poor† (P < .0001)
6/POG 8821, univariate;
67/POG 8821,
multivariate
Poor 4-yr EFS:
Cytogenetics 11q23 (P  .0013)
Poor 4-yr EFS:
FAB M5 (P  .0003)
Cytogenetics other than t(8;21), inv(16) (P 
.0001)
Better 4-yr EFS:
Cytogenetics inv(16) (P  .007)
t(8;21) (P  .014)
Normal karyotype (P  .012)
Single karyotypic abnormality (P  .0003)
Better 4-yr EFS:
Age >2 (P  .003)
WBC count <50 000/L at diagnosis (P 
.049)
Cytogenetics t(8;21), inv(16) (P  .0003)
normal chromosomes (P  .031)
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Cytotoxic Therapy with HSCT in Pediatric AML 19HERAPY-RELATED AML
One single-arm, noncomparative study on the use
f BMT in therapy-related AML is summarized as
ollows. Woodard et al. [56] reported outcomes of 38
ediatric (22 yr) patients treated with allo-BMT
matched sibling, n 16; mismatched family member,
 3; or matched unrelated donor, n  19) for
herapy-related AML (n  27, 71%) or therapy-re-
ated MDS (n 11) that developed after treatment for
prior hematologic malignancy or solid tumor. Me-
ian time from achievement of CR1 to allo-BMT was
ot reported. The 3-year OS and EFS for the 27
atients with therapy-related AML were 18.5  7.5%
nd 18.7  7.5%, respectively. The 3-year cumulative
isk of TRM was 59.6  8.4%.
ATE EFFECTS
Parsons et al. [57] performed a retrospective Qual-
ty-adjusted Time Without Symptoms of disease or
oxicity of treatment (Q-TWiST) analysis of the
OG 8821 [13] trial data to assess patients’ quality of
ife based on treatment modality (chemotherapy,
uto-BMT, or allo-BMT). Three clinical health states
ere deﬁned: TOX, the period of treatment-related
able 8. Continued
Reference No./Trial Univariate Analys
3/Taiwan POG Poor 5-yr OS:
WBC count >100 000/L at di
.003)
Induction response poor‡ (P 
Poor 5-yr EFS:
WBC count >100 000/L at di
.011)
Induction response poor‡ (P 
9/LAME 89/91 Better 5-yr OS:
WBC count <100 000/l at dia
.01)
Day 20 BM <20% blasts (P  .0
Allo-BMT in CR1 (P  .006)
Cytogenetics favorable  t(8;2
(16) vs others (P  .005)
Not significant for OS:
Gender, Age, CNS, FAB
Better 5-yr EFS:
WBC count <100 000/L at di
.02)
Not significant for EFS:
Age, FAB, percent blasts at da
cytogenetics
6/AIEOP LAM92 Poor 5-yr EFS:
Risk high§ (P  .04)
WBC count >100 000/L at di
not stated)
Induction response: good indicates no evidence of leukemia after
Medical Research Council (MRC) risk groups derived from cyto
inv(16), FAB M3; poor risk indicates monosomy 5 or 7, del 5
resistant disease (15% BM blasts after ﬁrst induction course);
Poor induction indicates 2 courses of therapy to attain remissio
Risk: standard indicates patients with FAB M2/M2 or M4eo subtyp
t(8;21), inv(16), or t(15;17); high risk, all other children.ymptomatic toxicities with grade 3; TWiST, the neriod representing the best possible quality of life
uring which patients experience no toxicities of treat-
ent or symptoms of disease; and REL, all time after
isease relapse. Intent-to-treat analysis assessed the
verage number of months patients spent in each state
uring the ﬁrst 60 months of follow-up. There was no
igniﬁcant difference between the chemotherapy (n 
17) and auto BMT (n  115) groups in time spent in
OX (2.2 versus 2.4 mo, P  .16) or TWiST (27.3
ersus 25.4 mo, P  .55). In contrast, patients in the
llo-BMT group (n  89) spent signiﬁcantly more
ime than those in the chemotherapy and auto-BMT
roups in TOX (3.4 mo, P  .001). Time spent in
WiST for the allo-BMT group was 33.9 months,
hich was signiﬁcantly longer than that in the auto-
MT group (P  .02) and the chemotherapy group
P  .06). Time after REL was not signiﬁcantly dif-
erent among the chemotherapy (6.2 mo), auto-BMT
3.5 mo), and allo-BMT (4.5 mo) groups.
Leung et al. [58] reported the incidence of late
ffects by treatment in 77 patients at a single institu-
ion who survived 10 years after the diagnosis of
ediatric AML. Treatment types included chemother-
py (group A, n  44), chemotherapy and cranial
rradiation (group B, n  18), or chemotherapy, cra-
Multivariate Analysis
(P 
Not reported
(P 
(P 
11), inv
Not reported
(P 
(P value
Not reported
.
s and response to induction: good risk indicates t(15;17), t(8;21),
mal chromosome 3, complex cytogenetics (5 abnormalities), or
rd risk indicates all others.
h Auer rods, or who did not have these characteristics but did haveis
agnosis
.002)
agnosis
.001)
gnosis
3)
1), t(9;
agnosis
y 20,
agnosis
2–3 wk
genetic
, abnor
standa
n.
es, witial irradiation, and allo-BMT (group C, n  15). At
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D. M. Oliansky et al.20median follow-up of 16.7 year, the development of
cademic difﬁculties and greater decrease in height Z
core* were signiﬁcantly associated with younger age
t diagnosis (P  .011 and .0084, respectively),
ounger age at initiation of radiation therapy (P 
011 and  .026, respectively), higher dose of cranial
adiation (P .010 and .0001, respectively), and treat-
ent groups B (P  .028 and .0001, respectively) and
(P .009 and .0008, respectively). Patients in treat-
ent group C compared with group A had a signiﬁ-
antly higher risk for a greater decrease in weight Z
core (P  .0005) and the development of growth
ormone deﬁciency (P  .003), hypothyroidism (P 
47), hypogonadism (P  .0001), infertility (P 
0001), and cataracts (P  .0001).
Leahey et al. [59] conducted a retrospective study
f long-term survivors of pediatric AML at a single
nstitution. Late effects in weight and height and in
ndocrine, ophthalmologic, renal, and cardiac func-
ions were compared in patients (25 years old at
ollow-up) treated with chemotherapy with/without
adiation therapy (n  26) or BMT with/without TBI
n  26) at mean follow-ups of 7.4 and 5.6 years,
espectively. The only statistically signiﬁcant differ-
nce between the 2 groups was in the higher use of
strogen supplementation in females who underwent
MT (n  9) versus chemotherapy (n  11; 67%
ersus 0%, P  .002).
Locatelli et al. [60] reported that, at a median
ollow-up of 5 years, 49 (33%) of 147 pediatric pa-
ients with AML surviving 18 months after auto-
MT had at least 1 late complication. The late effects
xamined were impairment in growth velocity (n 
1), abnormal thyroid (n  20) or cardiac (n  3)
unction, hypogonadism (n  13), and acquired sec-
ndary myelodysplasia (n 1). The use of TBI during
onditioning was the only factor signiﬁcantly associ-
ted with the development of late complications (data
ot provided).
Michel et al. [61] investigated late effects among
5 pediatric patients with AML treated with allo-
MT from an HLA-matched related donor after con-
itioning with Bu (oral)  Cy (n  26) or with TBI
n  19). Patients who received TBI versus Bu  Cy
ere signiﬁcantly more likely to have impaired growth
t a median follow-up of 5 year (P  .01) and an
ncreased probability of hypothyroidism at 6 years
P  .02). The 6-year probabilities of cataracts were
0  13% in the TBI group and 0% in the Bu  Cy
roup (P value not stated).
Z score statistic measures the distance in standard deviations of a
oample from the mean.ROGNOSTIC FACTORS
A comprehensive review of prognostic factors that
ffect the outcome of SCT in pediatric patients with
ML is beyond the scope of this evidence-based re-
iew. However, Tables 8 and 9 provide summaries of
hose prognostic factors that were identiﬁed through
nivariate and/or multivariate analyses as positively or
egatively affecting patient outcomes in the major
ooperative group, phase III studies presented earlier
n this review. Table 8 presents prognostic factors
elated to outcomes regardless of treatment, and Ta-
le 9 presents prognostic factors related to outcome
y treatment type.
REAS OF NEEDED RESEARCH
Clinical and translocational research in allo-SCT
hould focus on improving antileukemic treatment
fﬁcacy and decreasing toxicity of such treatment.
fter reviewing the evidence, the panel recommends
he following as the most important areas of needed
esearch.
. What is the role of risk group stratiﬁcation, in-
cluding the role of cytogenetics, in selection of
patients for allo-SCT, especially those in CR1?
. What is the appropriate timing and use of alter-
native donor SCT, given that matched unrelated
donor SCT appears to yield outcomes equivalent
to those of matched related donor SCT?
. What is the role of reduced intensity SCT (includ-
ing the use of ﬂudarabine-based preparative regi-
mens) and/or other immunomodulatory ap-
proaches to maximize the graft-versus-leukemic
effect? Can reduced intensity SCT be used as a
platform for vaccination strategies? Can reduced
intensity SCT decrease the incidence and severity
of late effects? Can the use of donor (and host)
genotyping aid in identifying better donor grafts
(ie, killer cell Ig-like receptor mismatching, phar-
macogenomic testing, etc)?
. What is the role of biologically targeted agents (ie,
tyrosine kinase inhibitors, farnesyl transferase in-
hibitors, Flt-3 inhibitors, etc) in the treatment of
AML, including induction, consolidation, condi-
tioning regimens, and after SCT?
ISCUSSION
The authors recommend methodology standard-
zation, including study design, endpoint deﬁnitions,
nd reporting of study results. Studies must stratify
esults by age and disease and give as much informa-
ion as possible on cytogenetics and other risk factors.
his information will facilitate disease- and age-spe-
iﬁc applications of therapy. In addition, publication
f preliminary analyses should be reserved for studies
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Cytotoxic Therapy with HSCT in Pediatric AML 21n which the trial was terminated early due to excessive
oxicity or to signiﬁcantly inferior or superior results.
or most studies, a minimum of 3 years of follow-up
n surviving patients is needed to detect signiﬁcant
ifferences between treatment arms. The authors ad-
ocate prompt reporting of mature data in full-length
anuscript format. Abstracts do not adequately con-
ey the full details of the study design or patient
haracteristics to meet evidence-based criteria for in-
lusion in systematic reviews or for making a true
ssessment of the widespread applicability or effect of
reatment outside the scope of the trial.
Many current therapies for cancer result from the
andomized clinical trial process. It is currently esti-
ated that 60% of pediatric cancer patients participate
n cancer clinical trials [68]. Due to the rarity of AML in
hildren, all pediatric patients with AML should be stud-
ed in large cooperative group settings to enroll enough
atients to answer clinical trial questions.
IMITATIONS OF THIS EVIDENCE-BASED REVIEW
There are limitations to any evidence-based re-
able 9. Prognostic Factors Related to Outcome (DFS, EFS, and/or OS
Reference No./Trial Univariate Analysis
1/CCG combined
trials
Not reported
2/CCG 2891 Better 8-yr OS:
Allo-BMT better than auto-BMT for
Age <1 yr (P  .03)
FAB M4 (P  .003)
Cytogenetics inv(16) (P  .04)
Better 8-yr OS:
Chemotherapy better than auto-BMT
(P  .009) for
Age <1 yr (P  .009)
Cytogenetics inv(16) (P  .05)
0/LAME 89/91 Poor 4-yr DFS:
Chemotherapy group
Age <1 yr (P < .01)
WBC count > 50 000/L at diagnosis
(P  .03)
FAB M5 vs others (P < .01)iew of the published literature. The criteria for this review included reliance on published data, speciﬁ-
ally peer-reviewed articles published since 1990. Un-
ublished data, which were not included in this re-
iew, often represent “negative” ﬁndings and do not
ndergo peer review. Also excluded were data pub-
ished in abstract form because the data are usually not
eer reviewed, are presented in an abbreviated format,
nd most often represent preliminary rather than ﬁnal
ata analyses.
Limitations speciﬁc to this review include the vari-
bility in reporting patient characteristics before SCT
nd changing treatment modalities over time. Chemo-
herapy regimens, particularly pre-SCT conditioning
egimens, and post-SCT supportive care have
hanged considerably over the 15 years of trials
ncluded in this review. Studies varied substantially in
tudy onset and endpoint deﬁnitions, conditioning
egimen drugs, and reporting of cytogenetic and other
isk data, making it difﬁcult to compare SCT out-
omes across studies. Randomized controlled trial
ata were lacking in many areas of this review, leading
o several treatment recommendations based on small
rospective studies and/or large retrospective registry
reatment Type
Multivariate Analysis
r 8-yr OS:
nor better than no donor for
BC count <50 000/L and >50 000/L at diagnosis (P  .028)
AB M1/M2 (P  .004; True for all FAB types, but survival rates
and P values not stated)
ytogenetics t(8;21) (P  .028)
r 8-yr DFS:
nor better than no donor for
BC count <50 000/L and >50 000/L at diagnosis (P  .008)
ytogenetics t(8;21) (P  .04)
ormal karyotype (P  .013)
reported
4-yr DFS:
emo group
ge <1 yr (P  .01)
AB M5 vs others (P  .01)
r 4-yr DFS:
T better than chemotherapy for
ge >1 yr (P  .01)
r 4-yr DFS:
T group
MT in CR1, yes vs no (P  .05)
significant for DFS:
T group
ge, WBC count at diagnosis, FAB, hepatosplenomegaly,
meningeal involvement), by T
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D. M. Oliansky et al.22llogeneic transplantation are limited by the inability
o provide level “1” evidence (ie, randomized con-
rolled trials) due to the low rate of patients random-
zed to the allo-SCT arm who would actually receive
he assigned treatment (35% of patients have a
atched related donor [69]). Therefore, for a trial
pplying biologic allocation of related allo-SCT, “2” is
he highest level of evidence that can be practically
sed.
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PPENDIX A. GLOSSARY OF TERMS
IEOP Associazione Italiana Ematologia ed Oncologia
Pediatrica
llo Allogeneic
ML Acute myeloid leukemia
NLL Acute non-lymphocytic leukemia
NZCCSG Australian and New Zealand Children’s Cancer
Study Group
PL Acute promyelocytic leukemia
uto Autologous
FM Berlin-Frankfurt-Munster
M Bone marrow
MT Bone marrow transplantation
u Busulfan
BT Cord blood transplantation
CG Children’s Cancer Group
ML Chronic Myeloid Leukemia
NS Central nervous system
R1 First complete remission
R2 Second complete remission
y Cyclophosphamide
FS Disease-free survival
S Down syndrome
BMT European Group of Blood and Marrow
Transplantation
FS Event-free survival
ORTC European Organization of Research andTreatment of CancerAB French-American-British morphology
classification
LA Human leukocyte antigen
AM Leucemia Acuta Mieloide
AME Leucemie Aigue Myeloblastique Enfant
FS Leukemia-free survival
DS Myelodysplastic syndrome
RC Medical Research Council
RD Matched related donor
UD Matched unrelated donor
OPHO Nordic Society for Paediatric Haematology and
Oncology
S Overall survival
B Peripheral blood
BSCT Peripheral blood stem cell transplantation
h Philadelphia chromosome positive
OG Pediatric Oncology Group
OL Quality of life
-TWiST Quality-adjusted time without symptoms or
treatment toxicity
CTs Randomized controlled trials
FS Relapse-free survival
CT Stem cell transplantation
-AML Therapy-related (or treatment-related) acute
myeloid leukemia
-MDS Therapy-related (or treatment-related)
myelodysplastic syndrome
POG Taiwan Pediatric Oncology Group
BI Total body irradiation
RM Treatment-related mortality
RD Unrelated donor
BC White blood cell
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